search
Back to results

Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma

Primary Purpose

Melasma

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Revlite Q switched Nd:YAG
Trivantage Q switched Nd: YAG
Sponsored by
Cynosure, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Melasma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subjects with Fitzpatrick Skin Type III-VI
  2. Subjects with mixed (epidermal and dermal) type melasma diagnosed by Wood's Lamp.
  3. Subjects who are over the age of 18 years of age
  4. The subject is willing and able to comply with study instructions and return to the clinic for required visits.
  5. The subject's melasma has persisted for greater than 6 months and has failed to respond to conventional treatment with hydroquinone cream or other topical lightening agents.

Exclusion Criteria:

  1. The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
  2. The subject has a history of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis.
  3. The subject has any skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy.
  4. The subject has an uncorrected coagulation defect or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy).
  5. The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
  6. The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days prior to entering this study.
  7. The subject has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines, etc.) within a timeframe where photosensitization from these drugs may still be present.
  8. The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.
  9. The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate).
  10. The subject has Diabetes Type 1 or 2.
  11. The subject has a sensitivity to hydroquinone or Retin-A.
  12. The subject has evidence of a compromised immune system or hepatitis.
  13. Has had microdermabrasion in past 3 months, other laser or Intense Pulsed Light treatment or chemical peels to the face in past 6 months, injectable fillers, topical retinoids, over-the-counter anti-aging products past 2 weeks.
  14. Has a history of keloids or hypertrophic scarring
  15. Has permanent make-up and/or is unwilling to refrain from using semi-permanent cosmetics during study

Sites / Locations

  • NY Laser and Skin Care

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Revlite Q switched Nd:YAG laser

TriVantage Q switched Nd:YAG laser

Arm Description

Revlite Q switched Nd:YAG laser 1064 nm

TriVantage Q switched Nd:YAG laser 1064nm

Outcomes

Primary Outcome Measures

Changes in Melasma Determined by Physician
The Global Aesthetic Improvement scale was used to determine the amount of improvement. This scale ranges from 1 to 5, where 1 is very much improved, 2 is much improved, 3 is improved, 4 is no change, and 5 is worsened.

Secondary Outcome Measures

Universal Pain Scale for Subject Tolerability
The subject pain tolerability was assessed using the Universal Pain Scale. This scale ranges from 0 (no pain) to 10 (worst pain possible).

Full Information

First Posted
December 6, 2012
Last Updated
December 3, 2020
Sponsor
Cynosure, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01745224
Brief Title
Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Terminated
Why Stopped
The study stopped because patient enrollment requirements were not met.
Study Start Date
July 2012 (undefined)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
July 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cynosure, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This proof of concept study will be conducted to assess the aesthetic improvement in refractory mixed type melasma in subjects treated with two FDA 510K approved devices: Q Switched Nd: YAG Laser vs. Alex TriVantage

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Melasma

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This was a comparative study where the device was used outside of the recommended treatment usage. It was used to assess the Revlite device for feasibility and not health outcomes.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Revlite Q switched Nd:YAG laser
Arm Type
Experimental
Arm Description
Revlite Q switched Nd:YAG laser 1064 nm
Arm Title
TriVantage Q switched Nd:YAG laser
Arm Type
Experimental
Arm Description
TriVantage Q switched Nd:YAG laser 1064nm
Intervention Type
Device
Intervention Name(s)
Revlite Q switched Nd:YAG
Intervention Description
Revlite Q switched Nd:YAG 1064nm
Intervention Type
Device
Intervention Name(s)
Trivantage Q switched Nd: YAG
Intervention Description
Trivantage Q switched Nd: YAG 1064nm
Primary Outcome Measure Information:
Title
Changes in Melasma Determined by Physician
Description
The Global Aesthetic Improvement scale was used to determine the amount of improvement. This scale ranges from 1 to 5, where 1 is very much improved, 2 is much improved, 3 is improved, 4 is no change, and 5 is worsened.
Time Frame
3 months post last treatment
Secondary Outcome Measure Information:
Title
Universal Pain Scale for Subject Tolerability
Description
The subject pain tolerability was assessed using the Universal Pain Scale. This scale ranges from 0 (no pain) to 10 (worst pain possible).
Time Frame
3 months post last treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects with Fitzpatrick Skin Type III-VI Subjects with mixed (epidermal and dermal) type melasma diagnosed by Wood's Lamp. Subjects who are over the age of 18 years of age The subject is willing and able to comply with study instructions and return to the clinic for required visits. The subject's melasma has persisted for greater than 6 months and has failed to respond to conventional treatment with hydroquinone cream or other topical lightening agents. Exclusion Criteria: The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period. The subject has a history of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis. The subject has any skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy. The subject has an uncorrected coagulation defect or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy). The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study. The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days prior to entering this study. The subject has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines, etc.) within a timeframe where photosensitization from these drugs may still be present. The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial. The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate). The subject has Diabetes Type 1 or 2. The subject has a sensitivity to hydroquinone or Retin-A. The subject has evidence of a compromised immune system or hepatitis. Has had microdermabrasion in past 3 months, other laser or Intense Pulsed Light treatment or chemical peels to the face in past 6 months, injectable fillers, topical retinoids, over-the-counter anti-aging products past 2 weeks. Has a history of keloids or hypertrophic scarring Has permanent make-up and/or is unwilling to refrain from using semi-permanent cosmetics during study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patricia Krantz
Organizational Affiliation
Cynosure, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
NY Laser and Skin Care
City
New York
State/Province
New York
ZIP/Postal Code
10028
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma

We'll reach out to this number within 24 hrs